Phase 2 Multiple Sclerosis Trial, Recruiting NCT04121468 Sponsor: The Hospital for Sick Children Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Phase 2 Multiple Sclerosis Trial, Recruiting

NCT04121468
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with MS that has affected the visual pathway at the front of the brain, and it has been more than 6 months since you had an episode of optic neuritis (inflammation of the eye nerve) or another MS flare-up
  • You are between 10 years old and 25 years and 11 months old
  • Specific eye tests (VEP and/or OCT scans) show certain signs of nerve damage or slowed nerve signals in at least one eye (confirm with trial site for exact measurements)
  • Your eye nerve layer thickness, measured by a scan, is not below a certain minimum level (confirm with trial site)
  • If you are already taking an MS medication, your dose and type of medication have not changed in the 6 months before joining the study
  • Your kidneys and liver are working well enough, based on blood tests appropriate for your age and sex
  • Your level of disability from MS falls within a certain range on a standard scale (confirm with trial site)
  • You are able to understand and communicate in English well enough to complete memory and thinking tests

Who may not be able to join:

  • You have a history of significant eye disease unrelated to MS
  • You have unstable or Type 1 (insulin-dependent) diabetes, or problems with acid levels in your blood
  • You have had episodes of very low blood sugar in the past for unknown reasons
  • You are already taking metformin (a diabetes medication)
  • You are currently using insulin
  • You are currently using another treatment aimed at repairing nerve coverings (confirm with trial site)
  • You have had a steroid treatment for an MS flare-up, or had a flare-up, within the 30 days before screening
  • You are taking certain other medications that may interact with metformin, such as some blood pressure or fluid medications (confirm with trial site for a full list)
  • Your blood lactate (a body chemical) levels are above a certain level
  • You are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: E. Ann Yeh, MA, MD, FRCPC, Dip ABPN, The Hospital for Sick Children

Phone: 416-813-7353

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
The Hospital for Sick Children
Registry
ClinicalTrials.gov
Start date
24 February 2020
Est. completion
1 March 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Number of patients with adverse events (safety and tolerability); Number of patients who were approached to participate, declined participation and consented to participate (recruitment); Proportion of patients who completed each visit within the trial (retention); Proportion of patients who completed each of the outcome measures at the appropriate time points (adherence with outcome measures); Number of patients enrolled in the study compared to the number of patients who were able to complete study measures (tolerability with outcome measures)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov